Clinical trials: Solid Tumors Harboring NTRK Fusion
Advanced Solid Malignant Tumors
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors
This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of DS-6051b in Japanese subjects with advanced solid malignant tumors harboring either a ROS1 or NTRK fusion gene.
- Trial name
- NCT02675491
- Testing
- DS-6051b
- Where
- 3 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- SCOUT (NCT02637687)
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- 45 sites in United States, Australia and 19 more
- Volunteers
- 154 people
- Sponsor
- Bayer
Solid Tumors Harboring NTRK Fusion
A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice
This is an observational study in which patient data from the past of adult people with solid tumors harboring NTRK gene fusion are studied.
- Trial name
- NCT05192642
- Testing
- Larotrectinib(Vitrakvi, BAY2757556), Data on other treatments
- Where
- United States
- Volunteers
- 368 people
- Sponsor
- Bayer
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion, Infantile Fibrosarcoma
A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database
This is an observational study in which data from the past of children and young people with a specific cancer, called NTRK gene fusion positive infantile fibrosarcoma (IFS) is studied.
- Trial name
- EPI VITRAKVI (NCT05236257)
- Testing
- Larotrectinib (Vitrakvi, BAY2757556), Standard of Care
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Bayer
Solid Tumors Harboring NTRK Fusion
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion).
- Trial name
- NCT03206931
- Testing
- Selitrectinib (BAY2731954)
- Sponsor
- Bayer
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is…
- Trial name
- ON-TRK (NCT04142437)
- Testing
- larotrectinib(Vitrakvi, BAY2757556)
- Where
- 47 sites in United States, Argentina and 13 more
- Volunteers
- 54 people
- Sponsor
- Bayer
Solid Tumors Harboring NTRK Fusion
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- NAVIGATE (NCT02576431)
- Testing
- BAY2757556 (Larotrectinib, Vitrakvi)
- Where
- 98 sites in United States, Argentina and 23 more
- Volunteers
- 215 people
- Sponsor
- Bayer
Non-Small Cell Lung Cancer
Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion
This observational study evaluates the real-world safety and effectiveness of repotrectinib in Korean participants with locally advanced or metastatic ROS1-positive non-small cell lung cancer or solid tumors harboring…
- Trial name
- NCT07599007
- Testing
- Repotrectinib
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects
This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect and Relative bioavailability of VC004 Capsules in healthy subjects
- Trial name
- NCT06529445
- Testing
- High Dose VC004 Capsules, Median Dose VC004 Capsules, Low Dose VC004 Capsules
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Solid Tumors Harboring NTRK Fusion
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
In this study, the researchers will compare 2 new tablet forms of BAY2731954 with liquid oral forms of BAY2731954. A maximum of 61 healthy volunteers aged 18 to 55 will be asked to participate. The study will have 2 parts.
- Trial name
- NCT04771390
- Testing
- Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Bayer
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- NCT03215511
- Testing
- Selitrectinib (BAY2731954)
- Where
- 29 sites in United States, Australia and 8 more
- Volunteers
- 81 people
- Sponsor
- Bayer
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of…
- Trial name
- NCT02122913
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bayer
Advanced Malignant Solid Neoplasm, Recurrent Ependymoma
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma
- Trial name
- NCT03213704
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 124 sites in United States, Puerto Rico
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes
Researchers want to learn more about the use of larotrectinib as a real-world treatment for tropomyosin receptor kinase fusion cancer, also called TRK fusion cancer.
- Trial name
- NCT04945330
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Bayer
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan
This is an observational study in which data from the past of people with solid tumors harboring an NTRK gene fusion in Japan are studied.
- Trial name
- NCT05793281
- Testing
- No Drug
- Where
- Japan
- Volunteers
- 46,621 people
- Sponsor
- Bayer
Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
- Trial name
- NCT05745623
- Testing
- ICP-723
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate pharmacokinetics of a single oral dose of VC004 capsules under fasting and fed conditions in healthy subjects.
- Trial name
- NCT05528120
- Testing
- VC004 Capsules
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Solid Tumors Harboring NTRK Fusion
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body
The researchers in this study want to gather information in healthy adult male participants about how the human body absorbs, distributes and excretes the drug selitrectinib including the effect of the interaction of food with…
- Trial name
- NCT04275960
- Testing
- Selitrectinib (BAY2731954)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Solid Tumors Harboring NTRK Fusion, NTRK
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
The goal of this clinical trial is to learn about the safety of drug CG001419. It also learn if drug CG001419 works to treat in locally advanced/metastatic adult solid tumours with NTRK gene fusions, NTRK gene point mutations…
- Conditions
- Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive
- Trial name
- NCT07394374
- Testing
- CG001419 tablets
- Where
- 6 sites in China
- Volunteers
- 42 people
- Sponsor
- Cullgen (Shanghai),Inc